Health ❯Healthcare ❯Pharmaceuticals ❯Drug Development

Eli Lilly

Oral GLP-1 Pill Orforglipron Delivers Phase III Weight Loss as Obesity Care Broadens Beyond Injections

Evidence this week underscores a shift to personalized obesity care built on behavior profiling alongside novel metabolic targets.

Lilly’s Orforglipron Pill Hits Phase 3 Goals, Clearing Path to Global Filings

Lilly’s Oral GLP-1 Pill Underperforms Wegovy in Late-Stage Trial

Mounjaro Rivals Trulicity in Cardiovascular Safety and Lowers All-Cause Mortality

Trump Tariffs Drive Corporate Forecast Cuts and Supply Chain Shifts

Novo Nordisk Seeks FDA Approval as Eli Lilly's Weight-Loss Pill Advances

IMF Warns of Rising Risks as U.S. Tariff Actions Shake Global Markets

U.S.-Japan Trade Talks Show Progress as Global Markets React

FDA Ends Shortage of Eli Lilly’s Weight-Loss Drug, Restricts Copycat Versions

Eli Lilly Shares Plunge After Disappointing Q3 Earnings and Sales